Antibacterial Agents TRIZ Cases

Removing the RHS secondary amine and using a 1,4-substituted piperidine linker preserves antibacterial activity while lowering hERG risk.

A mixed free and lipid-encapsulated inhaled antiinfective delivers immediate killing plus sustained lung exposure to limit rapid absorption and resistance.

Acid-labile nanoparticles disrupt bacterial adhesion on medical devices, preventing resistant biofilm formation without toxic antimicrobials.

Propylene glycol in water stabilizes dalbavancin injection, avoiding reconstitution while keeping impurities low at elevated temperatures.

1-Aminosulfonyl-2-carboxypyrrole inhibitors block metallo-beta-lactamases, restoring carbapenem efficacy against resistant Gram-negative bacteria.

Replacing unstable dichloropyrimidine with 4-chloro-6-methoxypyrimidine lifts sulfamonomethoxine yield above 91.5% and simplifies purification.

VHH antibodies bind ETEC adhesin proteins to block intestinal attachment and reduce diarrhea without relying on antibiotics.

A lignin-glucomannan supramolecular carrier forms a 3D hydrogen-bonded network that prevents phase separation in oral PDT formulations.

Modular 13-membered azaketolides vary ring substituents to improve Gram-negative antibacterial activity while simplifying macrolide synthesis.

Purified bacterial strains restore the gut microbiome to prevent C. difficile recurrence without donor-screening burdens of fecal transplantation.

A stepwise condensation, addition, cyclization, and acidification route raises sulfamerazine yield while lowering raw material cost and toxicity.

High-affinity N-terminal ADM binding stabilizes plasma ADM, preserves partial activity, and helps counter septic shock vasodilation.

Modular lipophosphonoxins selectively disrupt bacterial membranes to target resistant strains while lowering hemolysis and serum albumin binding.

Using Esc-COP-30 bacteriophage, this case shows selective lysis of pathogenic E. coli while reducing resistance pressure and sparing commensal bacteria.

Covalently linking antigen-binding moieties to mucin binders improves respiratory mucosal retention and counters clearance-driven efficacy loss.

A boron beta-lactamase inhibitor paired with oral ceftibuten restores activity against CRE and ESBL-producing gram-negative bacteria.

A sodium chloride and tea extract formulation boosts bioelectrical signaling through neural pathways to support tissue regeneration with less fibrosis.

A beta-lactamase inhibitor paired with meropenem restores activity against CRE in immunocompromised patients and helps reduce mortality.

Combining PD-1 binding with a second checkpoint target helps overcome tumor immune suppression and improve efficacy at lower concentrations.

Specific amino acid changes help alkaline phosphatase retain activity and stability in low-zinc conditions for inflammatory disease treatment.

A titanium-binding antimicrobial peptide coats dental implants to block biofilms without surface-damaging debridement.

An aqueous VHH-Fc antibody composition improves IL17A affinity while reducing aggregation, instability, and immunogenicity.

Sub-MIC keratinicyclin B and vancomycin work synergistically against C. difficile while sparing gut microbiota and reducing relapse.

Synergistic cannabinoid and antimicrobial combinations boost activity against resistant infections and biofilms while lowering dosage and side effects.

Direct detection of Borrelia peptidoglycan enables earlier, more specific Lyme diagnosis and supports hydrolase-based treatment.

Metal-triggered pyrazole thioamides activate at infection sites to hit multiple bacterial targets, lowering resistance risk and systemic toxicity.

Small molecules target essential bacterial pathways to inhibit gram-positive, gram-negative, and multidrug-resistant infections.

Humanized CDR and framework engineering improves β-glucan binding while limiting immunogenicity for fungal diagnosis and therapy.

Glycan profiling of IgG and IgM improves acute Lyme diagnosis, separates new from past infection, and helps track treatment response.

A bacteriophage endolysin fused with Cecropin A breaks the outer membrane barrier and kills Gram-negative bacteria at lower doses.

A non-fluorinated quinolone targets both P. acnes inhibition and inflammation control to address antibiotic resistance in acne treatment.

Benzamide analogues inhibit mycobacterial ATP synthesis and can synergize with bedaquiline to address MDR and XDR tuberculosis.

Specific N-terminal and amino acid substitutions in polymyxin derivatives preserve Gram-negative activity while lowering cytotoxicity and kidney exposure.

Novel simian adenoviral vectors reduce pre-existing Ad5 immunity while preserving strong immunogenicity for vaccine delivery.

A 12-herb TCM composition uses grouped roles and ultrasonic extraction to address residual pathogens, cough, fatigue, and Qi-Yin deficiency.

Small Gla domain peptides retain strong PtdS binding while staying below kidney filtration size for targeted diagnosis and therapy.

Pyrrole amide mineralocorticoid receptor antagonists address phototoxicity while maintaining treatment efficacy for hypertension and heart failure.

Controlling heavy metals below 350 ppb in aluminum-protein formulations reduces degradation and preserves vaccine shelf life.

Targets PqsR quorum sensing with inverse agonists that curb biofilm volume and virulence while improving stability, solubility, and selectivity.

By targeting the conserved evolvability factor Mfd, ARM-1 reduces bacterial mutagenesis and slows the emergence of antibiotic resistance.

Antibodies that bind deacetylated PNAG enable complement-mediated killing and biofilm disruption without relying on resistance-driving antibiotics.

Engineered ORF141-mutant staphylococcal phages make MRSA more susceptible to β-lactams while reducing virulence and staphyloxanthin production.

A plant-extract eluent and protective agent preserve microbiota viability, reduce odor, and improve storage stability for precise transplantation.

A linked dual-peptide protein resists stomach proteolysis while binding pathogen targets to help prevent or treat GI and pulmonary infections.

Positively charged block polypeptides target C. difficile spores and biofilms while helping preserve the gut microbiome during oral treatment.

A defined essential oil blend targets H. pylori, including resistant strains, while avoiding the gastrointestinal side effects of antibiotics.

Acidic pH with DEGEE preserves topical formulations without traditional antimicrobials, reducing toxicity while meeting pharmacopeia criteria.

Fatty acid attachment extends IL-22 circulation while preserving native activity and avoiding the immunogenicity seen with Fc fusion or PEGylation.

Empty cholesterol and sphingomyelin liposomes disrupt biofilm matrices and improve antibiotic susceptibility in persistent infections.

Beneficial intestinal strains preemptively occupy gut niches to suppress drug-resistant and pro-inflammatory bacteria after flora disruption.

Combining factor H binding protein with capsular saccharides overcomes insufficient cross-protective efficacy against diverse serogroups.

Esterifying astaxanthin with oleic acid resolves low serum levels and solubility limits in supplements.

Aminopyrimidinecarboxamides inhibit neutrophil recruitment and tumor angiogenesis by blocking ELR-CXC chemokine interactions at the CXCR2 receptor.

Chemically modified siRNA compounds administered directly to the spinal cord via intraparenchymal injection.

Ion exchange chromatography combined with reverse phase separation achieves 99% purity while resolving recovery rate trade-offs.

A traditional Chinese medicine composition treats viral infections using interferon mediation to inhibit replication.

A novel Lactobacillus sp. strain inhibits vaginal pathogens through hydrogen peroxide production and lactic acid secretion.

A method prepares optically active S-(-)-prulifloxacin by reacting S-(-)-ulifloxacin with a dioxolenone derivative in an organic solvent.

Synchronizes aerosol generation with patient inspiratory phases to prevent condensation losses in ventilator circuits.

Enriched halogenated tetraphenylchlorin atropisomer compositions generate stronger oxidative stress through selective light absorption.

Fungal-degraded date pit peptides treat infections without antibiotic residues, preventing resistance development.

Myoviridae bacteriophage Vib-PAP-4 selectively destroys Vibrio parahaemolyticus to resolve antibiotic resistance and environmental pollution in aquaculture.

Segmented synthesis of uncialamycin analogs overcomes production bottlenecks to deliver picomolar antitumor efficacy.

A nuclease composition breaks down extracellular nucleic acids on the ocular surface.

Screening IgA antibodies from breast milk to bind NEC-associated bacteria, reducing intestinal inflammation and disease severity in premature infants.

Combination product with antibiotic and resistant non-pathogenic microorganism prevents resistance emergence while reducing toxicity.

An immunogenic conjugate elicits a targeted immune response against poly-gamma-glutamic acid polypeptides in Staphylococcus epidermidis.

Fused amino pyridine compounds inhibit HSP90, addressing the lack of effective inhibitors for cancer and neurodegenerative diseases.

Halogenated tricyclic compounds restore beta-lactam efficacy against MRSA by reducing minimum inhibitory concentrations and disrupting biofilms.

Luminescence-based oximetry determines antibiotic efficacy by measuring phase angle shifts, eliminating culture delays.

Synergistic antibiofilm agents eradicate established biofilms and persister cells, overcoming standard treatment resistance.

Fused bicyclic pyrazole structures overcome antibiotic resistance in MRSA strains by modifying molecular parameters.

Carbohydrate-binding modules block pathogen attachment to cell surfaces, preventing infection without exposing cryptic receptors.

LGG-derived antimicrobial peptides disrupt bacterial membranes to lower APEC and Salmonella loads, avoiding antibiotic resistance development.

Crowberry endophyte peptides combat antibiotic resistance by maintaining stable efficacy against resistant microbial strains.

Pyridinecarboxamide compounds inhibit CXCR2 receptors, preventing excessive neutrophil accumulation and tissue damage in inflammatory disorders.

Pyrazine derivatives resolve isoform selectivity trade-offs by segmenting inhibition across specific PI3K subtypes.

Acidification precipitates proteins and nucleic acids from Streptococcus pneumoniae lysate to produce purified capsular polysaccharides.

Segmentation of the SP-R210 receptor into distinct isoforms enables precise antibody targeting, resolving specificity issues in influenza therapy.

Modifying the thiophene core structure overcomes drug resistance in rapidly mutating viruses like influenza and HIV.

Sequential cation exchange and hydrophobic interaction chromatography purifies recombinant G-CSF with high yield.

Standardized cranberry and propolis extracts reduce urinary infection risks while addressing antibiotic resistance.

A biodegradable sinus stent expands to maintain ostial patency while delivering therapeutic agents locally.

Imidazopyridine compounds inhibit Bruton's tyrosine kinase to treat autoimmune diseases and cancers without off-target effects.

Positively charged nanoparticles facilitate intracellular uptake of therapeutic agents via electrostatic interaction with cell membranes.

Supercritical carbon dioxide precipitation forms uniform protein microparticles, eliminating thermal denaturation and complex equipment requirements.

Extraction of specific recombinant antigens reduces production costs while maintaining comprehensive prevention coverage for Mycoplasma spp.

Synergistic fatty acids and chelating agents penetrate biofilms to eradicate pathogens while minimizing toxicity to mammalian tissues.

Chimeric OspA molecules merge distinct serotype regions to resolve the trade-off between broad Borrelia protection and complex vaccine composition.

Modular pyrrolopyridinone structures resolve therapeutic effectiveness versus target specificity trade-offs in cancer and inflammatory disease treatments.

Cilastatin acts as a competitive antagonist at megalin binding sites, preventing aminoglycoside-induced renal impairment.

Modifying substituents on the pyrazolo[3,4-d]pyrimidine core resolves the trade-off between pharmacological activity and pharmaceutical properties.

A dopa-modified hydrogel forms strong bonds with tissue through enzymatic crosslinking.

Shiga toxin A subunit scaffolds deliver heterologous epitopes to MHC class I molecules via engineered polypeptide sequences.

Formula I compounds inhibit bacterial polypeptide deformylase via hydroxamic acid coordination, achieving broad-spectrum activity against diverse strains.

Amino acid co-polymers disrupt microbial membranes to treat infections while reducing cytotoxicity risks associated with traditional peptides.